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Abstract: 
Clinical studies have indicated existence of an “obesity paradox” in patients with chronic heart 
failure (HF), i.e., reduced mortality among patients who have elevated body mass index (BMI) 
compared to normal weight reference groups. We aimed to investigate the relationship of BMI 
with all-cause and cardiovascular (CV) mortality and hospitalization in patients with chronic HF 
though a systematic review and meta-analysis of the literature. We searched Pub Med, CINAHL, 
Cochrane CENTRAL, Scopus, and EMBASE databases for studies reporting rate of total 
mortality, cardiac mortality and risk of hospitalization in patients with HF in various BMI 
categories [<20 (low); 20-24.9 (normal reference); 25-29.9 (overweight); 30-34.9 (obese); >=35 
(severely obese)]. Event rates were compared using a forest plot of relative risk using a random 
effects model assuming inter-study heterogeneity. Two study authors [AS, AV] independently 
reviewed the 124 articles and identified 6 for final analyses (N=22807). After mean follow up 
period of 2.85 years, the risk for adverse events was highest among patients with low BMI: Total 
mortality RR 1.27 [95% CI 1.17 – 1.37]; CV mortality1.20 [95% CI 1.01 -1.43]; and 
hospitalization 1.19 [95% CI 1.09 – 1.30].  Risk of CV mortality and hospitalization was lowest 
in overweight patients (RR0.79 [95% CI 0.70-0.90] and 0.92 [95% CI 0.86-0.97] respectively). 
Increasing degree of obesity failed to achieve a statistically significant effect on CV mortality 
(0.82 [0.64-1.05] and 0.71 [0.50-1.01] for obese and severely obese, respectively) and on 
hospitalization (0.99 [0.92-1.07] and 1.28 [0.88-1.87] for obese and severely obese, 
respectively). In conclusion, risk of total mortality and CV mortality and hospitalization was 
highest among chronic HF patients who were underweight as defined by low BMI, whereas risk 
of CV mortality and hospitalization was lowest in the overweight.  
Key words: Body mass index, heart failure 
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Introduction: 
        The association between BMI and all- cause and CV mortality and hospitalizations in HF is 
not fully understood. Due to contradictory results in various studies and lack of definitive data on 
prognostic value of BMI and its purposeful alteration in HF, the American College of Cardiology 
Foundation/American Heart Association do not provide any firm recommendations for 
purposeful weight loss in HF [1]. In the present study, the available evidence is systematically 
reviewed to examine the association between the most commonly used anthropometric measure 
of the degree of adiposity, namely the body BMI, with all- cause mortality and CV mortality and 
hospitalizations among patients with chronic HF. 
METHODS 
        Meta-analysis was performed in accordance with the Meta-Analysis of Observational 
Studies in Epidemiology (MOOSE) guidelines [2]. A checklist of each of the MOOSE criteria 
and how they were handled in our study is contained in Appendix Table 1. 
        We systematically searched PubMed, CINAHL, Cochrane CENTRAL, Scopus and Web of 
Science databases for all studies that reported total mortality, cardiac mortality and rate of 
hospitalization on the basis of BMI. All relevant combinations of the following keywords related 
to body mass (for example, BMI, body weight, obesity, overweight, central obesity), total 
mortality, CV events (for example, cardiac death, CV death, mortality), hospitalization, 
readmission and presence of HF (systolic HF, diastolic HF, cardiomyopathy, cardiac failure) 
were included for database search. The search was conducted from the inception of these 
databases to May 31, 2014. No language or age restrictions were applied. 
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        Clinical studies were included if the studies met the following criteria: (i) inclusion of 
patients with chronic HF, (ii) reported measures of total mortality, CV mortality and/or rate of 
hospitalization secondary to congestive HF exacerbation according to BMI. 
        We could not use the standard categorization of BMI groups because of the inconsistency of 
across studies. Thus, we arbitrarily assigned the low BMI group when BMI was the lowest and 
below 20, normal BMI if it was identical or close to 20–24·9, overweight if the BMI group was 
identical or close to 25–29·9, obesity if it was close or identical to 30–34·9, and severe obesity if 
BMI was 35 or greater. 
        Two independent reviewers (AS, AV) screened the titles and abstracts for relevance. 
Discrepancies between reviewers were discussed until consensus was reached. The manuscripts 
of selected titles/abstracts were reviewed for inclusion. Using the above selection criteria, two 
reviewers (AS, AV) independently determined the articles to be included or excluded. Data from 
the relevant articles were extracted using pre-defined extraction forms. Two independent 
reviewers (AS, AV) performed the data extraction. Any disagreements in data extraction were 
discussed until consensus was reached. Events for studies which reported outcome separately for 
patients with BMI >35 kg/m2 and > 40 kg/m2 were combined and reported as severely obese (> 35 
kg/m2). 
        Mix 2.0 Pro (Biostat XL) software was used to analyze the data. A random-effects model 
with inverse variance weighting was used to calculate pooled relative risks (and 95% CI). We 
assessed the three outcomes: total mortality, CV mortality and rate of hospitalization. 
Heterogeneity between studies was assessed using Cochrane’s Q test and I2 statistic, which 
denotes the percentage of total variation across studies that is a result of heterogeneity rather than 
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chance. Heterogeneity was considered significant if the p value was less than 0.05. Publication 
bias was assessed by Begg’s test and Egger’s regression test.  The influence of individual studies 
was examined by removing each study sequentially to assess the degree to which the meta-
analysis estimate depends on a particular study (exclusion sensitivity analysis). 
RESULTS 
        Six studies met inclusion/exclusion criteria (N=22,807) (Figure 1) [3-8]. Follow-up duration 
was from 1.5 years to 4.1years. Details of the studies are summarized in Table 1. Obese patients 
were younger than normal and low BMI patients on average by 4 and 7 years, respectively 
(Table 2). 
        The low BMI group had the greatest risk for total mortality, with a relative risk (RR) of 1.27 
(95% confidence interval [CI] 1.17 – 1.37), while overweight, obese and severely obese groups 
had lower relative risks of 0.78 [0.68-0.89], 0.79 [0.65-0.97], and 0.75 [0.57-0.98], respectively 
(Figures 2, 3 and Table 3). Heterogeneity analysis was significant across overweight (p=0.003, I2 
=72%), obese (p<0.001, I2 =81%) and severely obese (p=0.04, I2=77%) groups. There was no 
heterogeneity across the low BMI group (p =0.54, I2 =0%).  
        The low BMI group had the greatest risk for CV mortality (RR = 1.20 [1.01 -1.43]), while 
overweight had decreased risk compared with normal (0.79 [0.70-0.90]), and did not differ 
significantly from obese and severely obese groups (0.82 [0.64-1.05] and 0.71 [0.50-1.01], 
respectively [Figures 3, 4 and Table 3]). Heterogeneity analysis was significant across 
overweight (p=0.03, I2 =60%), obese (p<0.001, I2 =82%) and severely obese (p=0.04, I2=77%) 
groups. There was no heterogeneity across the low BMI group (p =0.57, I2 =0%).  
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        The risk for hospitalization secondary to HF exacerbation was highest in the low BMI group 
(1.19 [1.09 – 1.30]) and lowest in overweight group (0.92 [0.86-0.97]). The obese (0.99 [0.92-
1.07]) and severely obese group (1.28 [0.88-1.87]) did not have significantly different risk 
(Figures 3, 5 and Table 3). There was no significant heterogeneity among the low BMI (p=0.31, 
I2 =17%), overweight (p=0.31, I2 =17%) and obese groups (p=0.59, I2 =0%),but significant 
heterogeneity was present across the studies in the severely obese group (p =0.005, I2 =87%).  
DISCUSSION 
        Our results indicate that in patients with chronic HF, the risk of all-cause and CV mortality 
and hospitalization was highest among those with low BMI at the end of a mean follow up 
period of 2.85 years and lowest in the overweight BMI group. This finding is counterintuitive 
and supports the presumption of a strong “obesity (or ‘overweight’) paradox” (Figure 4). 
        Our results also show that, unlike less severe degrees of obesity, which seem to be 
associated with an obesity paradox, severe obesity is associated with quite poor overall CV 
outcomes, suggesting that the apparent protective effect of adiposity tends to disappear at more 
extreme levels of obesity.  This finding is consistent with previous studies; conceivably, it could 
be due to deleterious effect of extreme obesity on central and peripheral hemodynamics, as well 
as on cardiac structure and function [9, 10, 11]. Nonetheless, Oreopoulos et al reported lower all- 
cause mortality and CV mortality among HF patients who were overweight compared to normal 
weight patients [10]. However, to our knowledge, our study is the first meta-analysis to 
comprehensively evaluate the association between BMI, the most commonly used 
anthropometric parameter to assess the degree of adiposity, with all- cause and CV mortality and 
risk of hospitalization among patients with chronic HF. Our results demonstrate that increased 
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total mortality among underweight patients can be explained by the increased rates of CV 
mortality, as opposed to mortality from non-CV causes, including cancer. Recently, Shah et al 
confirmed existence of a global obesity paradox in patients with acutely decompensated HF, 
reporting lower 1-year mortality among patients with acute decompensated HF who have higher 
BMI despite heterogeneity in biochemical and clinical profiles, thus demonstrating that a lower 
BMI effectively defines risk of long-term mortality independently of other clinical and of 
biochemical indices [12]. 
        Several hypotheses have been proposed to explain obesity paradox in chronic HF [9, 13]. 
Clearly, HF is a catabolic state and cardiac cachexia is an independent predictor of CV mortality 
in patients with advanced HF [14]. Patients with higher BMI also have high- energy reserve 
(higher body fat and lean mass), which help them to deal effectively with the high-energy 
requirement of HF. Alternatively, low BMI may be a marker of the severity of HF which, by 
itself, is the basis of outcome. 
        Cytokines and neuroendocrine profiles of chronic HF patients who are overweight/obese 
differ from those who are underweight and might play a modulating role [15-20]. Soluble tumor 
necrosis factor-alpha (TNFα) receptor level has been shown to be correlated significantly with 
both BMI and percentage body fat, which could exert a protective role by neutralizing the 
circulating TNF in overweight/obese patients [15, 20]. Chronic HF patients in edematous states 
have higher circulating levels of bacterial lipopolysaccharide (LPS) [21], which acts as a very 
strong immune activator due to its ability to release of pro inflammatory cytokines from 
circulating immune competent cells [17, 21]. Higher levels of circulating lipoproteins found in 
overweight/obese HF patients may bind and then detoxify lipopolysaccharides and have a 
potential anti-inflammatory effect [15, 14, 21]. 
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        In our study obese patients were younger than normal patients and than low BMI patients, 
on average by 4 and 7 years, respectively. This could be due to early onset of HF among obese 
patients secondary to high prevalence of CAD, CV risk factors and metabolic derangement 
secondary to obesity [9, 10, 13, 16]. In addition, HF patients with higher BMI typically have 
higher arterial blood pressure than their leaner counterparts, which allow them to tolerate more 
cardio-protective medications, potentially at higher doses, including beta blockers, renin 
angiotensin aldosterone system  (RAAS) inhibitors, and mineralocorticoid receptor antagonists 
[9, 16].  Obese patients also have demonstrated an attenuated response to the RAAS, which may 
lead to a better HF prognosis [9, 16].  
       Parameters of central obesity, like waist circumference and waist-to –hip ratio, are more 
closely associated with progression of atherosclerosis and adverse CVD events as compared with 
BMI [22-24].  This could be due to failure of BMI as an anthropometric parameter to adequately 
assess distribution and degree of adiposity; also, BMI cannot differentiate between adipose tissue 
and lean body mass [25, 26]. Low BMI not only reflects low adiposity but also potentially lower 
body lean mass, which has been associated with poor cardiorespiratory fitness and muscular 
fitness, -both of which predict poor clinical outcomes [13, 27-29].  
        Our study, however, also has several potential limitations. First, the prevalence of various 
associated comorbidities, including detailed data on various CV risk factors and duration and 
severity of HF and etiology of HF among various categories of BMI, was not reported, and, 
hence, could not be analyzed in the present meta- analysis. Thus, it remains unclear whether our 
findings can be attributed to more advanced disease in patients with low BMI. Studies included 
in our analysis have not taken into consideration any unintentional weight loss among patients; 
therefore, we cannot rule out the possibility of residual confounding effects in our study. Further, 
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our study did not evaluate the impact of targeted weight reduction in various BMI categories, 
thus it is not clear if targeted weight loss in morbidly obese patient of weight gain in underweight 
patients is beneficial or not. These issues need to be addressed in randomized control trial before 
making any specific recommendations. Second, higher levels of physical activities has been 
shown to improve cardiovascular risk profile and poor cardiorespiratory fitness is a strongly 
associated with adverse clinical outcomes in chronic HF patients [30, 31]. However, as studies 
included in our meta-analysis did not report the data on physical activities on patients or its 
impact on clinical outcome, we were unable to assess this important question in our present 
study. Third, not all studies included in our analysis classified their patients using the standard 
BMI categories. In addition, parameters of central adiposity, estimation of body fat and lean 
body mass (or non-fat mass) were not provided in the studies included in our analysis, precluding 
assessment of the relationship between these important body composition parameters with 
various end points. Fourth, average follow up in our study was 2.85 years, which might not be 
long enough to evaluate the negative impact of obesity on various clinical end points.  
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FIGURE LEGENDS: 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow 
sheet 
Figure 2. Forest plot of total mortality for all studies 
Figure 3. Total mortality, cardiac mortality and hospitalization in all studies 
Figure 4. Forest plot of CV mortality for all studies 
Figure 5. Forest plot of hospitalization in all studies 
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Table 1. Baseline characteristics of studies 
*: single center study; a: Candesartan in Heart failure - Assessment of mortality and 
morbidity (CHARM); b: Digitalis Investigation Group (DIG) trial; c: Japanese Cardiac Registry 
of Heart Failure in Cardiology (JCARE-CARD);d: Japanese HF patients in the Chronic Heart 
Failure Analysis and Registry in the Tohoku District (CHART) study; e: Irbesartan in HF and 
PRESERVed Ejection fraction (I-PRESERVE) 
 
Author Sampl
e Size 
Mean 
Age 
(years) 
Male Follow 
up 
(years) 
NYHA 
Class 
Study population Post hoc analysis 
Kenchaiah et 
al 
7599 66 68% 3 II-IV CHARMa + 
Lavie et al 206 54 81% 1.5 I-III Single center 
study 
* 
Curtis et al 7767 64 75% 3 I-IV DIGb + 
Hamaguchi et 
al 
2488 70 60% 2.1 I-IV  JCARE-CARDc + 
Nochioka et al 972 68 65% 3.4 I-IV CHARTd 
 
+ 
 
Haass et al 4109 72 n/a 4.1 II-IV I-PRESERVEe + 
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Table 2. Mean age of patients in various BMI categories  
BMI group Mean age (in years) 
<20 70.6 
20–24·9 67.7 
25-29.9 66.2 
30-34.9 63.1 
≥35 64.3 
BMI: Body Mass Index 
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BMI <20 20-24.9 25-29.9 30-34.9 ≥35 
Total mortality 1.27 [1.17 – 
1.37] 
1 0.78 [0.68-
0.89] 
0.79 [0.65-
0.97] 
0.75 [0.57-
0.98] 
CV mortality 1.20 [1.01 -
1.43] 
1 0.79 [0.70-
0.90] 
0.82 [0.64-
1.05 
0.71 [0.50-
1.01] 
Hospitalization 1.19 [1.09 – 
1.30] 
1 0.92 [0.86-
0.97] 
0.99 [0.92-
1.07] 
1.28 [0.88-
1.87] 
BMI: Body Mass Index 
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Figure 1. PRISMA Flowsheet  
 
 
Records identified through 
database searching (n=724)  
Additional records identified 
through other sources (n=34) 
Records after duplicates removed (n=758) 
Records screened [title and abstract] 
(n=758)  
Records excluded [Case 
report, review, non 
human studies or studies 
not related to chronic 
heart failure and obesity 
(n=504) 
Full text articles screened (n=254) Full text articles excluded [not reporting 
outcome of interest] (n=248) 
Articles included (n=6) 
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MOOSE (Meta-analysis Of Observational Studies in Epidemiology) Checklist 
Title: Relationship of body mass index (BMI) with total mortality, cardiac mortality and risk of 
hospitalization in patients with chronic heart failure  
Abhishek Sharma, MD; Carl J. Lavie, MD; Jeffrey S. Borer, MD; Ajay Vallakati, MD; Sunny Goel, MD; 
Francisco Lopez-Jimenez, MD, MSc; Armin Arbab-Zadeh, MD, Ph.D; Debabrata Mukherjee, MD, MS; 
Jason Lazar, MD, MPH 
 
 
Criteria Brief description of how the criteria were handled in the 
meta-analysis 
Reporting of background should 
include 
 
√ Problem definition Clinical studies have indicated existence of an obesity paradox 
in patients with chronic heart failure (HF) i.e. reduced 
mortality among patients who have elevated body mass index 
(BMI) compared to normal weight reference groups. We aim to 
investigate the relationship of body mass index (BMI) with 
total mortality, cardiac mortality and risk of hospitalization in 
patients with chronic HF.  
√ Hypothesis statement Lower BMI is associated with worse clinical outcome in 
patients with chronic HF.  
√ Description of study outcomes Total mortality, cardiac mortality and risk of hospitalization  
√ Type of study designs used We include various retrospective and prospective comparative 
studies reporting total mortality, cardiac mortality and the risk 
of hospitalization among various BMI categories in patients 
with chronic HF.  
√ Study population We placed no restriction. 
 
Reporting of search strategy should 
include 
 
√ Qualifications of searchers The credentials of the two investigators AS and AV are 
indicated in the author list. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
√ Search strategy, including time 
period included in the synthesis 
and keywords 
PubMed (1965 – May 31, 2014) 
EMBASE (1974 – May 31, 2014) 
CINAHL (1982- May 31, 2014) 
Web of Science (1965- May 31, 2014) 
Cochrane Collaboration Central Register of Controlled Trials (-
May 31, 2014) 
 
√ Databases and registries searched PubMed; EMBASE; CINAHL; Web of Science; Cochrane 
CENTRAL 
 
√ Search software used, name and 
version, including special features 
We did not employ a search software 
√ Use of hand searching We hand-searched bibliographies of retrieved papers for 
additional references 
√ List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow 
chart 
√ Method of addressing articles 
published in languages other than 
English 
No language restriction was applied while searching various 
databases. Google translation was used to article published in 
language other than English. 
√ Method of handling abstracts and 
unpublished studies 
We contacted few authors for unpublished studies. 
√ Description of any contact with 
authors 
We contacted few authors who have reported few but not all 
outcome of interest. 
Reporting of methods should include  
√ Description of relevance or 
appropriateness of studies 
assembled for assessing the 
hypothesis to be tested 
Detailed inclusion and exclusion criteria were described in the 
methods section. 
√ Rationale for the selection and 
coding of data 
Data extracted from each of the studies were relevant to the 
population characteristics, study design, and outcomes. 
√ Assessment of confounding Methods section. The influence of individual studies was 
examined by removing each study at a time to assess the 
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degree to which meta-analysis estimate depends on a particular 
study (exclusion sensitivity analysis). Publication bias was 
assessed by Begg’s test and Egger’s regression test. A random-
effects model with inverse variance weighting was used to 
calculate the pooled correlation co-efficient and the 
corresponding confidence interval.   
√ Assessment of study quality, 
including blinding of quality 
assessors; stratification or 
regression on possible predictors 
of study results 
Described in the methods section. 
√ Assessment of heterogeneity Heterogeneity of the studies were explored within two types of 
study designs using Cochrane’s Q test of heterogeneity and I2 
statistic that provides the relative amount of variance of the 
summary effect due to the between-study heterogeneity. 
√ Description of statistical methods 
in sufficient detail to be replicated 
Description of methods of meta-analyses, sensitivity analyses, 
and assessment of publication bias are detailed in the methods 
section. 
√ Provision of appropriate tables 
and graphics 
Figures 1-5. Tables 1-3. 
Reporting of results should include  
√ Graph summarizing individual 
study estimates and overall 
estimate 
Figures 2-5. 
√ Table giving descriptive 
information for each study 
included 
Table 1. 
√ Results of sensitivity testing 
 
Results.  The influence of individual studies was examined by 
removing each study at a time to assess the degree to which 
meta-analysis estimate depends on a particular study (exclusion 
sensitivity analysis).  
√ Indication of statistical 
uncertainty of findings 
95% confidence intervals were presented with all summary 
estimates, I2 values and results of sensitivity analyses 
Reporting of discussion should 
include 
 
√ Quantitative assessment of bias Sensitivity analyses indicate heterogeneity in strengths of 
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association due to most common biases in observational 
studies.   
√ Justification for exclusion We excluded studies that had not reported total mortality, 
cardiac mortality and the risk of hospitalization among various 
BMI categories in patients with chronic HF.  
√ Assessment of quality of included 
studies 
We discussed the results of the sensitivity and heterogeneity 
analyses 
 
Reporting of conclusions should 
include 
 
√ Consideration of alternative 
explanations for observed results 
We discussed the potential failure of BMI as an anthropometric 
parameter to adequately assess degree and distribution of 
adiposity. We also discussed other potential biases including 
the potential unmeasured confounders that may have caused 
residual confounding. 
 
√ Generalization of the conclusions Risk of total mortality, cardiac mortality and hospitalization 
was highest among chronic heart failure patients who were 
underweight patients as defined by low BMI 
√ Guidelines for future research We recommend future studies to 
- Investigate this association and explore potential underlying 
mechanisms 
- Investigate other anthropometric parameters like waist to hip 
ratio, waist circumference to assess degree of adiposity and 
assessing prognosis in HF patients. 
 
√ Disclosure of funding source None 
 
